Publications
5891 Results
- Journal / Conference
- Science 319:1676-1679
- Year
- 2008
- Research Committee(s)
- Lymphoma
- Study Number(s)
- SWOG-8819
Oncogenic CARD11 mutations in human diffuse large B cell lymphoma [PMID: 183233416]
- Journal / Conference
- Best Practice & Research Clinical Hematology 21(1)21-28
- Year
- 2008
- Research Committee(s)
- Leukemia
- Study Number(s)
- SWOG-9031
Has gene expression profiling improved diagnosis, classification, and outcome prediction in AML? [PMID18342809]
- Journal / Conference
- Clinical Genitourinary Cancer, 6(2):103-109
- Year
- 2008
- Research Committee(s)
- Genitourinary
- Study Number(s)
- S0418
Southwest Oncology Group phase II study of ispinesib in androgen-independent prostate cancer (AIPC) previously treated with taxanes [PMID18824433]
- Journal / Conference
- Journal of Clinical Oncology 26(25):4109-4115
- Year
- 2008
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- C89803
Impact of body mass index and weight change after teatment on cancer recurrence and survival in patients with stage III colon cancer: findings from Cancer and Leukemia Group B 89803. [PMC2654367; PMID18757324]
- Journal / Conference
- Journal of Clinical Oncology 26(34):5638-5644
- Year
- 2008
- Research Committee(s)
- Breast and Molecular Epidemiology
Recommendations for collection and handling of specimens from group breast cancer clinical trials, from onsite collection through shipping to the central bank [PMC2651095; PMID18955459]
- Journal / Conference
- Blood 112(11):146, abst. 376
- Year
- 2008
- Research Committee(s)
- Lymphoma
- Study Number(s)
- SWOG-8809, S9800, S9911
MUM1 expression in follicular lymphoma is a poor prognostic marker in patients treated with immunochemotherapy (SWOG 9800/9911) but not chemotherapy alone (SWOG 8809): A Southwest Oncology Group correlative science study
- Journal / Conference
- San Antonio Breast Cancer Symposium, abstract #75
- Year
- 2008
- Research Committee(s)
- Breast
- Study Number(s)
- SWOG-9313
Multiplexed AQUA-based assessment of SWOG 9313 shows prognostic value of continuous variable assessment
- Journal / Conference
- Blood 112(11):1231, abst. #3598
- Year
- 2008
- Research Committee(s)
- Lymphoma
- Study Number(s)
- S0313
Effect of adding ibritumomab tiuxetan (Zevalin) radioimmunotherapy consolidation to three cycles of CHOP plus involved-field radiotherapy for high risk limited stage aggressive diffuse B-cell lymphoma (Southwest Oncology Group Study 0313)
- Journal / Conference
- Society of Urologic Oncology 2008 Annual Meeting (oral presentation)
- Year
- 2008
- Research Committee(s)
- Genitourinary
- Study Number(s)
- 4B951